Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This study planned to assess the effect on the reduction in rate of severe asthma
exacerbations of different dose levels of QGE031 in asthma patients that are inadequately
controlled with inhaled steroid plus beta-2 agonist medication with or without oral steroid.
However, this study was terminated due to the efficacy results from an interim analysis (at
the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754). Planned data
analyses were not performed for this study due to the early termination and the very limited
dataset (only 10 participants received study medication of the 440 participants planned).